MRI safety announcements
 A public health advisory from the US Food and Drug Administration (FDA) gives evidence that nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy has developed in at least 90 patients with moderate to end-stage kidney disease after they had a MRI or magnetic resonance angiography scan with a gadolinium- containing contrast agent.
Whenever possible, the agency said, clinicians must not expose patients with moderate to end-stage kidney disease to a gadolinium-containing contrast agent. If exposure is necessary, prompt dialysis after the imaging procedure should be considered.
For further information, visit the FDA website or the International Center for Nephrogenic Fibrosing Dermopathy Research (ICNFDR).
AZ aluminium oxygen cylinders
The MHRA has received two reports of AZ aluminium oxygen cylinders fitted with obsolete pin index valves. The valves contain a metal component that is sufficiently magnetic to make the cylinder potentially hazardous when used in an MRI environment.
Download the MHRA's full report, including advice on required action. PDF
Back | Top
|
